Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • HDAC
    (88)
  • Apoptosis
    (14)
  • PROTACs
    (6)
  • Autophagy
    (4)
  • PD-1/PD-L1
    (3)
  • Reactive Oxygen Species
    (3)
  • CDK
    (2)
  • DNA Methyltransferase
    (2)
  • Epigenetic Reader Domain
    (2)
  • Others
    (101)
Filter
Search Result
Results for "

hda

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    237
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Dye Reagents
    1
    TargetMol | Dye_Reagents
  • PROTAC Products
    12
    TargetMol | PROTAC
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    12
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Antibody Products
    9
    TargetMol | Antibody_Products
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
TCS HDAC6 20b
HDAC6-IN-7
T22159956154-63-5In house
TCS HDAC6 20b (HDAC6-IN-7) is a selective HDAC6 inhibitor that blocks the growth of breast cancer cells and may be used in the study of cancer and neurodegenerative diseases.
  • Inquiry Price
8-10 weeks
Size
QTY
HDAC8-IN-20a
HDAC8IN20a, HDAC8 inhibitor-20a, HDAC8 inhibitor 20a, HDAC8 IN 20a
T241331884231-52-0In house
HDAC8-IN-20a (HDAC8 inhibitor-20a) is a potent and selective HDAC8 inhibitor with an IC50 of 27 nM. HDAC8-IN-20a blocks activation of growth receptor survival signals.
  • Inquiry Price
6-8 weeks
Size
QTY
mtor/hdac-in-1
T633992815286-02-1In house
mTOR HDAC-IN-1 (Compound 50) is a dual inhibitor of mTOR and HDAC, with IC50 values of 0.49 nM and 0.91 nM, respectively, holding potential as an anti-cancer agent [1].
  • Inquiry Price
3-6 months
Size
QTY
mTOR/HDAC-IN-1 HCl
mTOR HDAC-IN-1 HCl(2815286-02-1 Free base)
T63399L In house
mTOR HDAC-IN-1 HCl is a potent dual inhibitor of mTOR and HDAC with potential anti-inflammatory, anti-proliferative, autophagy and apoptosis-inducing effects for cancer research.
  • Inquiry Price
Size
QTY
HDAC6 degrader 9c
T697532235382-05-3In house
HDAC6 degrader 9c is a small molecule histone deacetylase 6 (HDAC6) degrader that can be used to study cancer or other diseases.
  • Inquiry Price
6-8 weeks
Size
QTY
BChE/HDAC6-IN-2
T776582925457-33-4In house
BChE HDAC6-IN-2 is a selective and potent dual inhibitor of BChE and HDAC6 with neuroprotective and reactive oxygen species (ROS) scavenging activity. BChE HDAC6-IN-2 is a metal ion co-agonist that inhibits tau phosphorylation and can be used in the study of immune and neurological diseases.
  • Inquiry Price
4-6 weeks
Size
QTY
HDAOS
T1935382692-88-4
HDAOS, a novel Trinder's reagent, is widely utilized in diagnostic and biochemical tests.
  • Inquiry Price
4-6 weeks
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-4
T115421252003-13-6
HDAC-IN-4, a selective HDAC6 and HDAC10 inhibitor (pIC50s: 7.2 and 6.8 in the BRET assay), exhibits antitumoral activity.
  • Inquiry Price
7-10 days
Size
QTY
HDAC-IN-7
T2025743420-02-2
HDAC-IN-7, an analogue of Tucidinostat (Chidamide), is a HDAC inhibitor. HDAC-IN-7 inhibits acetylation of histone protein H3 and induces apoptosis in human colon cancer cell lines[1].
  • Inquiry Price
Size
QTY
HDAC1/5-IN-1
T50084380463-49-0
(2E)-N-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-enamide is a compound used as a molecular structural unit.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-40
T600822463198-51-6
HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with a Ki of 60 nM for HDAC2 and 30 nM for HDAC6, exhibiting antitumor effects.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-52
T678782075787-77-6
HDAC-IN-52, a pyridine-containing HDAC inhibitor, effectively inhibits HDAC1, HDAC2, HDAC3, and HDAC10 with IC50 values of 0.189, 0.227, 0.440, and 0.446 μM, respectively. HDAC-IN-52 can be used in cancer research.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-51
T73181
HDAC-IN-51 is an HDAC inhibitor.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-57
T773342716217-79-5
HDAC-IN-57 is an orally active pan-inhibitor of histone deacetylase (HDAC), inhibiting HDAC1, HDAC2, HDAC6, and HDAC8 with IC50 values of 2.07 nM, 4.71 nM, 2.4 nM, and 107 nM, respectively. HDAC-IN-57 inhibits LSD1 with an IC50 value of 1.34 μΜ. HDAC-IN-57 has anti-tumor activity and can induce apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-3
GSK3117391A
T85081018673-42-1
HDAC-IN-3 (GSK3117391A) is a potent histone deacetylase (HDAC) inhibitor, and treatment chronic inflammatory disorders.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HDAC-IN-5
T115431314890-51-1
HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor [inducing apoptosis, with potential antineoplastic (antitumor) and chemopreventive activities], inhibiting cell proliferation and regulating cell differentiation (IC50=0.0056 µM, 72 h) in murine erythroleukemia cells.
  • Inquiry Price
6-8 weeks
Size
QTY
HDACs/mTOR Inhibitor 1
T115442271413-06-8
HDACs mTOR Inhibitor 1 is a dual HDAC and mammalian target of Rapamycin (mTOR) inhibitor for treating hematologic malignancies, with IC50 values of 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR, and PI3Kα, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
IDO1 and HDAC1 Inhibitor
T116252227044-16-6
IDO1 and HDAC1 Inhibitor is a dual IDO1 and HDAC1 inhibitor (IC50s: 69.0 nM and 66.5 nM).
  • Inquiry Price
6-8 weeks
Size
QTY
PI3K/HDAC-IN-1
T124552361418-52-0
PI3K HDAC-IN-1 is a potent dual inhibitor of PI3K and HDAC, with IC50 values of 8.1 nM and 1.4 nM, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
HDAC-IN-77
T200029
HDAC-IN-77 (HL-5s), an HDAC inhibitor, has the capability to induce ferroptosis and suppress the Nrf2 HO-1 signaling pathway. This compound is utilized in cancer research.
  • Inquiry Price
Size
QTY
HDAC-IN-76
T200090
HDAC-IN-76 (compound 6i), a histone deacetylase (HDAC) inhibitor, demonstrates robust antimalarial activity, particularly against the asexual blood stages of Plasmodium. The compound exhibits potent efficacy with IC 50 values of 30 nM and 98 nM against Pf3D7 (chloroquine drug-susceptible strain) and PfDd2 (chloroquine drug-resistant strain), respectively. Moreover, HDAC-IN-76 shows selective inhibition towards parasites, displaying IC 50 values of 7 nM and 9 nM against human HDAC1 and HDAC6, respectively, and effectively inhibits PfHDAC1.
  • Inquiry Price
Size
QTY
STAT3/HDAC-IN-2
T200341
STAT3 HDAC-IN-2 (compound 18), a dual inhibitor of STAT3 and HDAC, promotes autophagy and apoptosis. This compound features an amphiphilic hydroxamic acid hybrid structure, derived from the natural product isopropanol lactone (IAL), and functions as a nanoscale anticancer agent. It has the ability to self-assemble into nanoparticles in aqueous environments, leading to enhanced tumor tissue accumulation, increased cellular uptake, and improved anticancer efficacy compared to its free state.
  • Inquiry Price
Size
QTY
c-Met/HDAC-IN-4
T200367
c-Met HDAC-IN-4, a dual inhibitor of c-Met HDAC, exhibits an IC 50 value of 28.92 nM for c-Met. This compound effectively induces G 0 G 1 phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells. Additionally, c-Met HDAC-IN-4 suppresses both the proliferation and invasion of breast cancer cell lines.
  • Inquiry Price
Size
QTY
HDAC8-IN-12
T2003833028095-13-5
HDAC8-IN-12 (compound 5k), a non-hydroxamic acid derivative, serves as a selective HDAC8 inhibitor with an IC 50 of 0.12 nM and demonstrates potent efficacy against breast cancer. This compound enhances anti-tumor immunity by activating T cells, elevating M1 macrophage levels, and reducing M2 macrophage proportions. In an orthotopic mouse model of breast cancer, HDAC8-IN-12, administered at 50 mg kg, effectively suppresses tumor growth.
  • Inquiry Price
8-10 weeks
Size
QTY